Hostname: page-component-7479d7b7d-68ccn Total loading time: 0 Render date: 2024-07-10T15:28:50.247Z Has data issue: false hasContentIssue false
  • English
  • Français

Antiprogestin Drugs: Ethical, Legal and Medical Issues

Published online by Cambridge University Press:  29 April 2021

Rebecca J. Cook  and
David A. Grimes
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
Law, Medicine and Healthcare , Volume 20 , Issue 3 , Fall 1992 , pp. 149 - 153
Copyright
© 1992 American Society of Law, Medicine & Ethics

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Glasier, A., Thong, K.J., Dewar, M., et al., “Comparison of Mifepristone (RU 486) and High Dose Estrogen-Progestogen for Emergency Postcoital Contraception”, New England Journal of Medicine 1992, forthcoming.CrossRefGoogle Scholar
Grimes, D.A. and Cook, R.J. [editorial] “Mifepristone (RU 486): An Abortifacient to Prevent Induced Abortion?” New England Journal of Medicine 1992, forthcoming.Google Scholar